Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 76 Publications

14 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK0JIQ> MYjJR|UxRTVwN{C1JEDPxE1i NEnIb2YyQDV3OU[xNy=>
KP6.3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\CTWo1KGR? M4jFSGlEPTB;MUCuOFI5KM7:TTC= NXrQO|FzOTh3NUm2NVM>
KP7.7 NYfGe4xZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7ROEBl NES5OpRKSzVyPUW3JI5OKA>? NXXRV3dzOTh3NUm2NVM>
KB2P3.4 NUnpOIxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DScVQh\A>? NHzjUpRKSzVyPUGyOEBOKA>? NUXqeYhkOTh3NUm2NVM>
KB2P1.21 M4\sW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm0JIQ> NFKzTo9KSzVyPUi5NFchdk1i MmHSNVg2PTl4MUO=
U373-MG MoLVR5l1d3SxeHnjJGF{e2G7 NEnRNGQyKM7:TTC= Mmr1NlQhcA>? MWPJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 NUDW[JVXOTh7NUS3NVI>
T98G NH;xc2ZEgXSxdH;4bYMhSXO|YYm= M3LMcFEh|ryPIB?= MoPSNlQhcA>? M4D4PGlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NVPHPJZxOTh7NUS3NVI>
U87-MG M{HzZmN6fG:2b4jpZ{BCe3OjeR?= NIPEPVkyKM7:TTC= NIP3Z4QzPCCq MWrJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6 NFfaSIoyQDl3NEexNi=>
UVW NXf4RVI3S3m2b4TvfIlkKEG|c3H5 NHfyRlQ2ODBibl2= MU[yOEBp Mm\qTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? M2[0VVE5QTV2N{Gy
HeLa NF;id|RHfW6ldHnvckBCe3OjeR?= Mlq5OVAxKG6P MWO0JIg> NV3xSpZoS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| MU[xPFk2PDdzMh?=
HeLa Ml;0SpVv[3Srb36gRZN{[Xl? NEHlcY4yKM7:TTC= MWOyOEBp MnvOSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? M2jEcFE5QTV2N{Gy
T98G M2f0T2Z2dmO2aX;uJGF{e2G7 MoO4NUDPxE1i NW\BeJhPOjRiaB?= MoLKSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? M3\HbFE5QTV2N{Gy
L3 NGjKNmFEgXSxdH;4bYMhSXO|YYm= MYC1JO69VSB? NH7Oe3c6PiCq NHfUfVdFVVOR MnjhV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs NHS3XpQzODF{NES1PS=>
Granta-519 NGLlZVZEgXSxdH;4bYMhSXO|YYm= MYO1JO69VSB? MlnXPVYhcA>? NHjDNWZFVVOR MlPTV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? M4DqW|IxOTJ2NEW5
BT NVnxU2w{S3m2b4TvfIlkKEG|c3H5 NUH0d4l[PSEQvF2g NV35TWx5QTZiaB?= MnXvSG1UVw>? NYHVWJhlW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MWeyNFEzPDR3OR?=
UPN2 NHPVNZVEgXSxdH;4bYMhSXO|YYm= NUOxc4diPSEQvF2g NHv4fIk6PiCq MnrISG1UVw>? NX3pb|lNW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= NUXGSYFVOjBzMkS0OVk>
HBL-2 M4D2V2N6fG:2b4jpZ{BCe3OjeR?= M4DSbVUh|ryPIB?= Ml23PVYhcA>? MXrEUXNQ M1LWS3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M{ewVVIxOTJ2NEW5
JVM-2 M4rP[WN6fG:2b4jpZ{BCe3OjeR?= MX:1JO69VSB? M37ZNFk3KGh? NIHUNJhFVVOR M4rLRnNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MVKyNFEzPDR3OR?=
Z138 M2rkNWN6fG:2b4jpZ{BCe3OjeR?= MkDVOUDPxE1i NHfRfpk6PiCq MXPEUXNQ MUPTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MoXFNlAyOjR2NUm=
RWPE NVXJfFV7UW64YYPpeoUhSXO|YYm= NXzKN5ZGOjVizszN NHn6PGI1QCCq MYPEUXNQ NIDmVFJUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v NXTXblJ7OjF3N{W4OlU>
VCaP NWf5SYN{UW64YYPpeoUhSXO|YYm= NVK5PGR7OjVizszN NVvTW4JlPDhiaB?= Mk[zSG1UVw>? M{jJXXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> M3\X[FIyPTd3OE[1
Mouse H2AX−/− ES Cells NXHqZXl2S3m2b4TvfIlkKEG|c3H5 MX6yMlUh|ryP MVmyNEBp NIDoTXZUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> M{HaOFI{OzV3NEi5
Mouse ATM−/− ES Cells MljIR5l1d3SxeHnjJGF{e2G7 NI\xWYczNjVizszN Ml;1NlAhcA>? M2TmU3Nq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> MWGyN|M2PTR6OR?=
H1650 M2n1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:2bpVTOjBizszN M1zq[FE1PCCq MnrSTWM2OD1zNT60O{DPxE1? NUTR[ll1OjN{M{m4NFk>
H1650PTEN+ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDmR|gzOCEQvF2= NFzvO3YyPDRiaB?= MkfMTWM2OD13MD64N{DPxE1? NHPV[3UzOzJ|OUiwPS=>
PC-9 NXPBbZZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHBNlAh|ryP NUj3VFBlOTR2IHi= MoDhTWM2OD13Lki4JO69VQ>? MUeyN|I{QThyOR?=
PC-9PTEN− M2iyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlOwNlAh|ryP M33YUlE1PCCq MYLJR|UxRTZwNUKg{txO NYDmSFFqOjN{M{m4NFk>
MDA-MB-231 NFvWZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonQOUBl[Xl? M4S4bGlEPTB;Nj65JO69VQ>? M4flZVI{PzZyNEm2
MDA-MB-468 NW\FNJJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL6OUBl[Xl? M3XUNWlEPTB;NT6wJO69VQ>? MVSyN|c3ODR7Nh?=
BT20 NFO0PVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi1JIRigQ>? NWHmXHp[UUN3ME23Mlch|ryP M2jRdVI{PzZyNEm2
HCC1143 NVi4OmxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK5PZQ2KGSjeR?= M3y4PGlEPTB;MUGuNUDPxE1? NIPqRXkzOzd4MES5Oi=>
HCC1937 NUe5RpRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK1JIRigQ>? MmH2TWM2OD1zMj62JO69VQ>? MXOyN|c3ODR7Nh?=
Hs578t M3Pu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXwZmgyPSCmYYm= NV3XZmh3UUN3ME21MlYh|ryP MW[yN|c3ODR7Nh?=
Hs578t(si) NWfTXoptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjURZE2KGSjeR?= MUTJR|UxRTdwNTFOwG0> MknYNlM4PjB2OU[=
BT474 M{fuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWq1JIRigQ>? MlHoTWM2OD1zOT64JO69VQ>? M{\lN|I{PzZyNEm2
JIMT1 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[xOlUh\GG7 NVvHdFlSUUN3ME23Mlch|ryP NXfDZWJmOjN5NkC0PVY>
SKBR3 M2ToS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;LT|dUPSCmYYm= NYDCd28{UUN3ME2xNU4yKM7:TR?= MljHNlM4PjB2OU[=
SUM159 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnvNGg2KGSjeR?= NG\odFJKSzVyPUSuNkDPxE1? M4jPTlI{PzZyNEm2
CAMA1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXq1JIRigQ>? NYD4WHI1UUN3ME2xOU45KM7:TR?= MXGyN|c3ODR7Nh?=
MCF7 MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjxfW5oPSCmYYm= MXrJR|UxRTVwODFOwG0> M{Dvb|I{PzZyNEm2
T47D M3zvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PqNlUh\GG7 NGLDWWFKSzVyPUmuOkDPxE1? MYqyN|c3ODR7Nh?=
HCT116 M3GzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXH[G93OTByIN88US=> MXS0PEBp NYPwV4drTE2VTx?= MoPaTWM2OD1{LkWg{txOKA>? Mn\sNlQ2Pzd7NEG=
SW1116 NGrvd|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHkNVAxKM7:TR?= MWm0PEBp NXjDZ3d7TE2VTx?= NH\Dco5KSzVyPUGwNEDPxE1? NG\kXZYzPDV5N{m0NS=>
HT29 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjDZ2kyODBizszN NEjVbno1QCCq MonmSG1UVw>? M4TTTGlEPTB;MUSuO{DPxE1? Ml\pNlQ2Pzd7NEG=
LoVo NWeyXoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSwNVAxKM7:TR?= Mo\OOFghcA>? M1PaXmROW09? M3LWOmlEPTB;MUOuOEDPxE1? NHLjU40zPDV5N{m0NS=>
HCT-15 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHrNVAxKM7:TR?= M2T1[FQ5KGh? MYfEUXNQ MkDVTWM2OD1zMDFOwG0> NXK5[WVnOjR3N{e5OFE>
SW48 M1rs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PldlExOCEQvF2= NILReoo1QCCq MoTYSG1UVw>? M4DHcGlEPTB;OT61JO69VQ>? MYiyOFU4Pzl2MR?=
C-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf5NVAxKM7:TR?= MWS0PEBp NYPxd|hoTE2VTx?= NWT1TpRyUUN3ME23MlYh|ryP MUKyOFU4Pzl2MR?=
RKO MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK3[WgyODBizszN MV:0PEBp M2TzTWROW09? NGHuR4hKSzVyPUWuPUDPxE1? NWHLfGxtOjR3N{e5OFE>
HCT116 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX2xNFAh|ryP MUO0PEBp MmnFSG1UVw>? MXfQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MUGyOFU4Pzl2MR?=
SW1116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrjfld7OTByIN88US=> NFLDSZA1QCCq NWjQ[JByTE2VTx?= M2nLbHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MoWzNlQ2Pzd7NEG=
HT29 NWTsZ|NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyxNFAh|ryP MX[0PEBp M3;2XWROW09? NFi2ZnhRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MV6yOFU4Pzl2MR?=
LoVo MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfzNVAxKM7:TR?= MXq0PEBp MUfEUXNQ M4fn[HBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NF;1RlYzPDV5N{m0NS=>
SW48 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xNFAh|ryP M{fFUlQ5KGh? NFnhNmtFVVOR MkfJVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? NYj3[XVjOjR3N{e5OFE>
C-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW0dGl2OTByIN88US=> Mn;NOFghcA>? M2T5R2ROW09? NVH1OYRsWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NUSz[npnOjR3N{e5OFE>
RKO M2XrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNFAh|ryP NVjyPVJPPDhiaB?= MVjEUXNQ MYPQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh M2niN|I1PTd5OUSx
HCT116 MXjGeY5kfGmxbjDBd5NigQ>? NWrrT|BtOTBibl2= NUfa[5BVOTJiaB?= M2\IT2ROW09? NWj2[YtzUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 M2DmcFI1PTd5OUSx
HT29 MWLGeY5kfGmxbjDBd5NigQ>? NIeye2syOCCwTR?= MormNVIhcA>? MVvEUXNQ M2HUN2lv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= M{PCZVI1PTd5OUSx
TE-6 NVfmUmI1TnWwY4Tpc44hSXO|YYm= M{HSPVUh|ryPIB?= MYWxNkBp MWfEUXNQ NVHYTmRxUW6mdXPld{BIOi:PIHHydoV{fA>? NUfqdHNnOjR{MUmxOlQ>
TE-6 M4PpTWZ2dmO2aX;uJGF{e2G7 MWO1JO69VSB? M3\WRVI1KGh? NIHZPXVFVVOR MmKwTY5kemWjc3XzJIlvKGSxdXLs[UB{fHKjbnSgZpJm[Wu|IDjEV2J{MQ>? MW[yOFIyQTF4NB?=
Hep3B M3ruTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\WOFAh|ryPIB?= NFGy[5c4OiCq NFy3SWdFVVOR NIr3eolUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? M4jNWlI2ODd{N{Wy
Huh7 M4rzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPOWnBPPDBizszNJC=> MVu3NkBp NFq1Z2ZFVVOR NWHHRpg6W3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? NHzUdHczPTB5Mke1Ni=>
Hep3B NXuwZ4tKTnWwY4Tpc44hSXO|YYm= NWPibG9nPDBizszNJC=> MlyzNlQhcA>? MXrEUXNQ NFi1b4NKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG= NVvJVos4OjVyN{K3OVI>
Huh7 NWHq[ZR[TnWwY4Tpc44hSXO|YYm= NXv6TY5IPDBizszNJC=> MWGyOEBp NG[2TW1FVVOR MnTnTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT M2HMPFI2ODd{N{Wy
Hep3B NXPlcXNtTnWwY4Tpc44hSXO|YYm= MUm0NEDPxE1i M1jIXlI1KGh? MVrEUXNQ M{DpO2lv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= NX\IXmtYOjVyN{K3OVI>
Huh7 NETTXJBHfW6ldHnvckBCe3OjeR?= MnPMOFAh|ryPIB?= NFfhVYgzPCCq NEn6SGlFVVOR MU\JcoR2[2W|IHPlcIwh[XW2b4DoZYd6KHerdHigSGhOTVF? Ml\iNlUxPzJ5NUK=
SGC-7901 NIS4TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonsN|DDqM7:TR?= NFrJW5g1QCCq NF3wdnBFVVOR MUPCcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi= MnPKNlU4PjdyN{[=
COLO-800 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vKfGlEPTB;MD60OFE3PCEQvF2= MljvV2FPT0WU
EoL-1- NELlO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNU[0OFYh|ryP NI\YdHhUSU6JRWK=
NCI-H209 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nubWlEPTB;MD65NVU2PiEQvF2= NIXESIhUSU6JRWK=
ES1 NWjzTGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMUG0NFgh|ryP M33HOHNCVkeHUh?=
NKM-1 NFjWZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDxTWM2OD1zLkK1N|Q4KM7:TR?= M2LEVnNCVkeHUh?=
NTERA-S-cl-D1 M3;6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFwM{OzOFEh|ryP NHvWXlJUSU6JRWK=
MHH-ES-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrReGlKSzVyPUGuOlIxPjdizszN M2i4XnNCVkeHUh?=
ES8 NXPteFZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDYTWM2OD1zLkeyOFE1KM7:TR?= MVzTRW5ITVJ?
NCI-H720 NX3WcIpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK0TXllUUN3ME2yMlIxPjl7IN88US=> NE\adW1USU6JRWK=
EW-3 M3[wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zab2lEPTB;Mj6yO|U{PCEQvF2= M4rIR3NCVkeHUh?=
D-566MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfFOJU6UUN3ME2yMlQ1PTZ6IN88US=> NGnITVlUSU6JRWK=
697 MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwOESxO|Mh|ryP MlPHV2FPT0WU
ES5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGryN4xKSzVyPUKuPFgyQDlizszN MnrJV2FPT0WU
COLO-684 NG[3TVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTNwNUG2PVYh|ryP M2LOT3NCVkeHUh?=
ML-2 NVnTcW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTNwNkCwOVgh|ryP MkHQV2FPT0WU
MC-IXC M2[1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLidJNKSzVyPUOuOlM{QTNizszN MnK5V2FPT0WU
DB M3zifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjKTnhVUUN3ME2zMlY2PDR6IN88US=> NFvycpdUSU6JRWK=
HCC2218 NVfrO2xqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTYboNMUUN3ME2zMlc{OTB|IN88US=> MYTTRW5ITVJ?
NCI-H510A MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz2N3NNUUN3ME2zMlgzPzJ2IN88US=> MULTRW5ITVJ?
NCI-H526 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rUR2lEPTB;Mz64Olk2QCEQvF2= M2TVZ3NCVkeHUh?=
MV-4-11 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXKZ2lKSzVyPUSuNVM{OzRizszN M{HNenNCVkeHUh?=
PA-1 NYn0WFZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTRwMkWyPUDPxE1? NWHCO285W0GQR1XS
EW-22 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nQS2lEPTB;ND6zOVg3KM7:TR?= NWDqO2pPW0GQR1XS
KASUMI-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonITWM2OD12LkSwNVA6KM7:TR?= Moj0V2FPT0WU
LU-139 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fyTmlEPTB;ND63OVgzQSEQvF2= NFnudGhUSU6JRWK=
SBC-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nDbmlEPTB;ND64NFkxQCEQvF2= MofNV2FPT0WU
H4 NWfkVpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rRcGlEPTB;ND64PVQ1OyEQvF2= NUP6TlZEW0GQR1XS
EW-11 M{ixOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV63dI96UUN3ME21MlA5ODd{IN88US=> NFnvb|JUSU6JRWK=
NBsusSR MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT5eXdVUUN3ME21MlEzODV3IN88US=> MV7TRW5ITVJ?
RPMI-8226 MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PpcmlEPTB;NT6xOVI1PCEQvF2= NGS4TVdUSU6JRWK=
DEL NVG3dWRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HPXWlEPTB;NT6yNFAxPiEQvF2= MkLVV2FPT0WU
ES4 M4DpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHhdXFKSzVyPUWuOVE{QDlizszN NEPJTWxUSU6JRWK=
GCT M3TVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILzZlVKSzVyPUWuOVY5PTZizszN NIHEc4FUSU6JRWK=
NCI-H1048 NXvzWZdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV6zNVlpUUN3ME21Mlk4Ojd|IN88US=> MnnSV2FPT0WU
NCI-SNU-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4D0emlEPTB;Nj6wNlIh|ryP MnnXV2FPT0WU
ES7 Ml3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTZwMEO1O|ch|ryP MlnLV2FPT0WU
SW982 NF\2S2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17hOGlEPTB;Nj6wPVE{PyEQvF2= NHTFSmpUSU6JRWK=
L-363 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PWbmlEPTB;Nj6zN|k4PCEQvF2= NIrWUJZUSU6JRWK=
HT-1080 NILvW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PXUWlEPTB;Nj60PVY5OyEQvF2= MkK3V2FPT0WU
HAL-01 M1rQZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqwUno4UUN3ME22MlUyODlizszN NGL5WoJUSU6JRWK=
NB14 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTZwNkSwN|kh|ryP NFG3O5FUSU6JRWK=
EW-13 NWXScWw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX3TWM2OD14Lke3OFI1KM7:TR?= NVPpOIZTW0GQR1XS
NY MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnEN2RFUUN3ME22Mlk1PjB3IN88US=> NYHMbHhUW0GQR1XS
NCI-SNU-5 M325cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTdwMUC0N|Mh|ryP MXPTRW5ITVJ?
MS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGS2V2pKSzVyPUeuNVc1QTRizszN NXfHVHZWW0GQR1XS
EW-16 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r5TmlEPTB;Nz6zNVg3OSEQvF2= NWSwRYxoW0GQR1XS
LU-65 NUDJSZk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwNEi0NVch|ryP MXrTRW5ITVJ?
HGC-27 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTdwN{KxO|Mh|ryP MmG1V2FPT0WU
CTB-1 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvuT3BZUUN3ME23Mlc3OTd3IN88US=> NHvYeWtUSU6JRWK=
5637 NYXHeHplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwOUK4OkDPxE1? NFLZUYFUSU6JRWK=
U251 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnZTWM2OD15Lkm0NFE3KM7:TR?= NF22fXJUSU6JRWK=
HOS NUTsPG1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTtXmZKSzVyPUiuNlMxODdizszN MmPTV2FPT0WU
DOHH-2 NYT1bWNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRThwMkO1PEDPxE1? NYHw[mxoW0GQR1XS
EW-1 NUPSNHRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRThwM{CwPFgh|ryP MXfTRW5ITVJ?
BV-173 M3;hZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1m3SWlEPTB;OD61OVU1KM7:TR?= MlLaV2FPT0WU
8-MG-BA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XxfGlEPTB;OD62PFk5QCEQvF2= M3T6ZXNCVkeHUh?=
NB69 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDzZY9KSzVyPUiuO|A6OjFizszN Mn3BV2FPT0WU
NCI-H69 NYPr[ppJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;5[GlEPTB;OT65NFk3OSEQvF2= NWPt[WhsW0GQR1XS
RS4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;GWpdKSzVyPUGxMlIzODhizszN M1XzR3NCVkeHUh?=
ONS-76 NWDodo92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTFzLkK5OFch|ryP MXvTRW5ITVJ?
SF539 MnrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFzLkS4PFkh|ryP MlzvV2FPT0WU
HuO-3N1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLkW3PVYh|ryP NFLXdIZUSU6JRWK=
NCI-H1651 M1PQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF{LkOxNVUh|ryP M2HScHNCVkeHUh?=
KARPAS-45 NX\HTo1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF{LkO3OkDPxE1? M1v4V3NCVkeHUh?=
SK-NEP-1 NUfNbZRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrQTWM2OD1zMj60OlA6KM7:TR?= NWrRZZNGW0GQR1XS
LAMA-84 MnOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnESZVsUUN3ME2xN{4yODl3IN88US=> M3fKNnNCVkeHUh?=
NCI-H1155 NVzme3o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj3XmpoUUN3ME2xN{4zQDV4IN88US=> M3vKOnNCVkeHUh?=
CTV-1 NW\Fd5dtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\JcWlEPTB;MUOuOFQ2KM7:TR?= NFzoUlNUSU6JRWK=
QIMR-WIL NWrJeHJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nnb2lEPTB;MUOuO|gyPCEQvF2= MYjTRW5ITVJ?
H9 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLsWmxyUUN3ME2xN{45PDd3IN88US=> Mm[wV2FPT0WU
SK-MEL-1 NFftOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i3cWlEPTB;MUOuPVM1PyEQvF2= Mn7lV2FPT0WU
HD-MY-Z MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDlTWM2OD1zND6wOlM4KM7:TR?= M3XNOXNCVkeHUh?=
TI-73 MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjY[G9KSzVyPUG0MlI{PTZizszN MmDQV2FPT0WU
JVM-3 NY[0XZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3tcJBKSzVyPUG1MlU4OTZizszN NGXG[3lUSU6JRWK=
D-247MG NVLOUItNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O2dGlEPTB;MUWuOVk{KM7:TR?= NFXOWmRUSU6JRWK=
VA-ES-BJ NGnLc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HGc2lEPTB;MUWuOlA6PyEQvF2= MlH4V2FPT0WU
NOS-1 M{\aRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfT[GczUUN3ME2xOU43PTJ{IN88US=> NUHWTIpHW0GQR1XS
MOLT-4 NXf5N|JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PnbWlEPTB;MU[uO|UzKM7:TR?= M2\Se3NCVkeHUh?=
Mo-T Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnaS5dQUUN3ME2xO{4xQDR7IN88US=> NHvYdXlUSU6JRWK=
NCI-H1770 NGXnUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX5c45KSzVyPUG3MlE2PDNizszN M3y1OHNCVkeHUh?=
COLO-320-HSR M4G3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fkcmlEPTB;MUeuNVgzPyEQvF2= NVzlemdtW0GQR1XS
TE-12 M3T4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPzR5VKSzVyPUG3MlcxPTRizszN NELuTXZUSU6JRWK=
NCI-H82 M4jUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPoV|c4UUN3ME2xO{45PzJ6IN88US=> MX\TRW5ITVJ?
NEC8 MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofmTWM2OD1zOD6xN|E3KM7:TR?= MWHTRW5ITVJ?
HSC-3 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorKTWM2OD1zOD63OFE1KM7:TR?= Mn;zV2FPT0WU
NCI-H1092 M4Xnb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HENmlEPTB;MUiuO|U6PSEQvF2= MXHTRW5ITVJ?
NCI-H292 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnLWnVUUUN3ME2xPU4xPDh7IN88US=> MkXWV2FPT0WU
L-428 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jqdGlEPTB;MUmuOVU6KM7:TR?= MlPqV2FPT0WU
LU-134-A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTrN|FKSzVyPUG5MlU4OiEQvF2= MoPvV2FPT0WU
GI-ME-N MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnhSFJqUUN3ME2xPU42PzR5IN88US=> MV\TRW5ITVJ?
ALL-PO NHqzcHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF7LkW5O|Ih|ryP MWLTRW5ITVJ?
D-283MED MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF7LkmxOUDPxE1? M2foeHNCVkeHUh?=
D-423MG NIP2NYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DL[2lEPTB;MUmuPVk3PyEQvF2= NHjWc41USU6JRWK=
CAKI-1 NUnKSI93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPQTWM2OD1{MD6yNlE6KM7:TR?= M2q2R3NCVkeHUh?=
ETK-1 NIPv[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DDXGlEPTB;MkCuNlYyPSEQvF2= MmjuV2FPT0WU
G-402 MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP2SHFKSzVyPUKwMlU{OzRizszN NVO3XY52W0GQR1XS
HL-60 NXT1fmxqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHTWM2OD1{MT6xOlE{KM7:TR?= M1rCSnNCVkeHUh?=
A2058 M{O5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHPNWNKSzVyPUKxMlQ1PzdizszN MkDIV2FPT0WU
CHP-212 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHiZmdQUUN3ME2yNU46ODVzIN88US=> M2faNnNCVkeHUh?=
KY821 NXS3OXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJzLkm3OUDPxE1? M3HrbnNCVkeHUh?=
TYK-nu MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ{LkC2OVEh|ryP MXfTRW5ITVJ?
JVM-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ{LkK5PFMh|ryP NXHCWm5[W0GQR1XS
KU812 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXITWM2OD1{Mj63N|EzKM7:TR?= NISzOGxUSU6JRWK=
MKN28 M{jVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ{LkmwNVUh|ryP NILtUm9USU6JRWK=
ECC10 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;Ce2lEPTB;MkOuO|QyKM7:TR?= NYO5e2JHW0GQR1XS
BHT-101 MkXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJ2LkCwNFgh|ryP MXHTRW5ITVJ?
DU-4475 NGjyTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoD5TWM2OD1{ND6zN|M4KM7:TR?= MWrTRW5ITVJ?
769-P NVrmcoNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[yc2lEPTB;MkSuPFQ3PiEQvF2= M2DHO3NCVkeHUh?=
HEC-1 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJ3LkS0OUDPxE1? M3fiTnNCVkeHUh?=
MOLT-13 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L5WGlEPTB;MkWuOVM{OSEQvF2= MYDTRW5ITVJ?
8505C MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTJ4LkS5O|ch|ryP MmDLV2FPT0WU
GB-1 NGHwTIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHsUG5LUUN3ME2yOk44OTd4IN88US=> NESzRVVUSU6JRWK=
SF126 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXJcpJEUUN3ME2yOk44PjR6IN88US=> NYC3NmF2W0GQR1XS
A4-Fuk NW\iRYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn3TWM2OD1{Nz6xNlcyKM7:TR?= MWfTRW5ITVJ?
OVCAR-8 NYLVN3NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm2TWM2OD1{Nz6xOVM6KM7:TR?= MULTRW5ITVJ?
NCI-H1304 NYjEOI5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTHTWM2OD1{Nz61OEDPxE1? Ml\RV2FPT0WU
GR-ST MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJ6LkC0O{DPxE1? MYjTRW5ITVJ?
G-401 MoDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHL1RmpKSzVyPUK4MlUxQTZizszN MlHSV2FPT0WU
LXF-289 M3XDT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfpTWM2OD1{OD61OlUyKM7:TR?= NX\wXmx3W0GQR1XS
DBTRG-05MG M1nB[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiTWM2OD1{OD65NlA1KM7:TR?= MWfTRW5ITVJ?
YKG-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm4TWM2OD1{OT64Olgh|ryP NXyxb|V[W0GQR1XS
GAMG MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ7Lkm5N{DPxE1? NYjKfnlNW0GQR1XS
HCT-116 Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nrOGlEPTB;M{CuNFU1QCEQvF2= MnvIV2FPT0WU
S-117 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;HbVNKSzVyPUOxMlIzPTdizszN NIrwN4JUSU6JRWK=
NCI-H1693 NFnBU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2O3WmlEPTB;M{OuOlU1OiEQvF2= NFjsUHBUSU6JRWK=
A427 M4W2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDvRpZKSzVyPUOzMlk6PzZizszN M2DlV3NCVkeHUh?=
HT-29 NWfLN3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTN2Lk[wN|Ih|ryP Mn36V2FPT0WU
P12-ICHIKAWA Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljSTWM2OD1|ND63OFkyKM7:TR?= MVfTRW5ITVJ?
CAL-51 M1G4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN3LkC3NFkh|ryP MkPpV2FPT0WU
Ramos-2G6-4C10 MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTN3LkK0NlUh|ryP MWjTRW5ITVJ?
SCH M1qxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHmTWM2OD1|Nj60NVc1KM7:TR?= M3nBNnNCVkeHUh?=
SK-MEL-24 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XYR2lEPTB;M{[uPVA1PCEQvF2= M{nzfHNCVkeHUh?=
SW1573 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTN6LkeyNVYh|ryP MlnsV2FPT0WU
BALL-1 M1TSUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jyRmlEPTB;M{muNlEzQSEQvF2= NYDTd|NRW0GQR1XS
BE-13 NFHkV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzmcFZUUUN3ME2zPU4{OjlizszN MYnTRW5ITVJ?
GI-1 MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTN7Lki2OFch|ryP MVTTRW5ITVJ?
GOTO M2mxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7WdG8zUUN3ME2zPU46OTN7IN88US=> MYXTRW5ITVJ?
A673 M{nQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G1NmlEPTB;NEGuNFM1OyEQvF2= NHfzSmZUSU6JRWK=
KG-1 NEHjboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjTTWM2OD12Mz6zPVQh|ryP NGD2bppUSU6JRWK=
GP5d NUHVUI9sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTR2LkC2OlYh|ryP MojjV2FPT0WU
MFM-223 NEK5NYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXQOHlKSzVyPUS0MlEzOjhizszN NX30fZVwW0GQR1XS
OAW-42 Mn3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC4cXNKSzVyPUS0MlI3PDNizszN M2DEbHNCVkeHUh?=
C8166 NIL1[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYKzemtpUUN3ME20OU4xQDJ{IN88US=> NGO1fHpUSU6JRWK=
LU-99A NFfjZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3iTWM2OD12Nj6xN|IzKM7:TR?= NUezOJBNW0GQR1XS
NCI-H23 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPkc3lKSzVyPUS2MlE4QDVizszN NHX0XZBUSU6JRWK=
HO-1-N-1 NIP5fIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonzTWM2OD12Nz6wPVk5KM7:TR?= Ml\tV2FPT0WU
A3-KAW MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3MVW1KSzVyPUS3MlExODdizszN MnLSV2FPT0WU
CGTH-W-1 NIfucIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPxZ|F[UUN3ME20O{42ODZ7IN88US=> NXfqdpdTW0GQR1XS
DJM-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknETWM2OD12Nz61OFE{KM7:TR?= MmfEV2FPT0WU
A101D MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe0UYhKSzVyPUS3MlY{PTdizszN NVPpV|NvW0GQR1XS
BB30-HNC NGDu[ohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGyTWM2OD12OD6zNFczKM7:TR?= MmmwV2FPT0WU
T98G MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGybIpjUUN3ME20PE41PjN|IN88US=> M1TMOnNCVkeHUh?=
NCI-H1573 NGDFdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrqSFFSUUN3ME20PU41PDZ{IN88US=> M{LxPXNCVkeHUh?=
MEG-01 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\NWXlKSzVyPUS5Mlc1OTFizszN NWXQcGhbW0GQR1XS
WM-115 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTR7LkmyNlIh|ryP MkTEV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

Related Antibodies

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID